99mTechnetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7–14) as a Targeted Imaging Agent with MicroSPECT in a PC-3 Prostate Cancer Xenograft Model

2011 ◽  
Vol 8 (4) ◽  
pp. 1165-1173 ◽  
Author(s):  
Hildo J. K. Ananias ◽  
Zilin Yu ◽  
Rudi A. Dierckx ◽  
Christophe van der Wiele ◽  
Wijnand Helfrich ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Xenograft Model ◽  
Imaging Agent ◽  
Targeted Imaging

scholarly journals Detection of Early Prostate Cancer Using a Hepsin-Targeted Imaging Agent

2008 ◽  
Vol 68 (7) ◽  
pp. 2286-2291 ◽  
Author(s):  
Kimberly A. Kelly ◽  
Sunita R. Setlur ◽  
Robert Ross ◽  
Rajesh Anbazhagan ◽  
Peter Waterman ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Imaging Agent ◽  
Targeted Imaging ◽  
Early Prostate Cancer

Altered steroid profiles in prostate cancer xenograft model with low ADRB2 levels

2016 ◽  
Author(s):  
Hakon Ramberg ◽  
Ralf Kellman ◽  
Peder Rustoen Braadland ◽  
Elin Staerli ◽  
Stein Waagene ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Xenograft Model ◽  
Steroid Profiles

scholarly journals Biodistribution and internal radiation dosimetry of a companion diagnostic radiopharmaceutical, [68Ga]PSMA-11, in subcutaneous prostate cancer xenograft model mice

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Su Bin Kim ◽  
In Ho Song ◽  
Yoo Sung Song ◽  
Byung Chul Lee ◽  
Arun Gupta ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Dosimetry ◽  
Xenograft Model ◽  
Absorbed Dose ◽  
Patient Specific ◽  
Internal Radiation ◽  
Washout Phase ◽  
Heterogeneous Tissue ◽  
Organ Level ◽  
Reported Data

Abstract[68Ga]PSMA-11 is a prostate-specific membrane antigen (PSMA)-targeting radiopharmaceutical for diagnostic PET imaging. Its application can be extended to targeted radionuclide therapy (TRT). In this study, we characterize the biodistribution and pharmacokinetics of [68Ga]PSMA-11 in PSMA-positive and negative (22Rv1 and PC3, respectively) tumor-bearing mice and subsequently estimated its internal radiation dosimetry via voxel-level dosimetry using a dedicated Monte Carlo simulation to evaluate the absorbed dose in the tumor directly. Consequently, this approach overcomes the drawbacks of the conventional organ-level (or phantom-based) method. The kidneys and urinary bladder both showed substantial accumulation of [68Ga]PSMA-11 without exhibiting a washout phase during the study. For the tumor, a peak concentration of 4.5 ± 0.7 %ID/g occurred 90 min after [68Ga]PSMA-11 injection. The voxel- and organ-level methods both determined that the highest absorbed dose occurred in the kidneys (0.209 ± 0.005 Gy/MBq and 0.492 ± 0.059 Gy/MBq, respectively). Using voxel-level dosimetry, the absorbed dose in the tumor was estimated as 0.024 ± 0.003 Gy/MBq. The biodistribution and pharmacokinetics of [68Ga]PSMA-11 in various organs of subcutaneous prostate cancer xenograft model mice were consistent with reported data for prostate cancer patients. Therefore, our data supports the use of voxel-level dosimetry in TRT to deliver personalized dosimetry considering patient-specific heterogeneous tissue compositions and activity distributions.

scholarly journals Synthesis and fluorine-18 radiolabeling of a phospholipid as a PET imaging agent for prostate cancer

2021 ◽  
Vol 93 ◽  
pp. 37-45
Author(s):  
Kim H. Kwan ◽  
Ingrid J.G. Burvenich ◽  
Margaret M. Centenera ◽  
Yit Wooi Goh ◽  
Angela Rigopoulos ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Pet Imaging ◽  
Imaging Agent

Abstract 1392: Synergistic antitumor efficacy of radium-223 in combination with enzalutamide in the intratibial LNCaP prostate cancer xenograft model

2021 ◽  
Author(s):  
Mari I. Suominen ◽  
Matias Knuuttila ◽  
Jukka Vääräniemi ◽  
Birgitta Sjöholm ◽  
Esa Alhoniemi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Xenograft Model ◽  
Antitumor Efficacy ◽  
Radium 223

scholarly journals Development and Characterization of a Spontaneously Metastatic Patient-Derived Xenograft Model of Human Prostate Cancer

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Tobias Lange ◽  
Su Jung Oh-Hohenhorst ◽  
Simon A. Joosse ◽  
Klaus Pantel ◽  
Oliver Hahn ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Xenograft Model ◽  
Human Prostate ◽  
Human Prostate Cancer ◽  
Patient Derived Xenograft

Intermittent androgen suppression in the LuCaP 23.12 prostate cancer xenograft model

The Prostate ◽  
2000 ◽  
Vol 43 (1) ◽  
pp. 63-70 ◽  
Author(s):  
Kent R. Buhler ◽  
Richard A. Santucci ◽  
Ramin A. Royai ◽  
Sarah C. Whitney ◽  
Robert L. Vessella ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Xenograft Model ◽  
Intermittent Androgen Suppression ◽  
Androgen Suppression
Sign in / Sign up

Export Citation Format

Share Document